Anzeige
Mehr »
Freitag, 20.02.2026 - Börsentäglich über 12.000 News
Goldaktie mit Newsflow: Ein Gold-Asset in der Champions League der Geologie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSAQ | ISIN: GB00BK80TJ35 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PHYSITRACK PLC Chart 1 Jahr
5-Tage-Chart
PHYSITRACK PLC 5-Tage-Chart
ACCESS Newswire
198 Leser
Artikel bewerten:
(1)

Physitrack PLC Announces Intention to Implement Share Buyback Program

Physitrack's Board of Directors has approved the intention to implement a share buyback program (the "SBB"), subject to lender consent and prevailing market conditions.

LONDON, GB / ACCESS Newswire / February 20, 2026 / Physitrack PLC (Nasdaq First North:PTRK) ("Physitrack" or the "Company") today announces that its Board of Directors has approved the intention to implement a share buyback program (the "SBB"), subject to lender consent and prevailing market conditions.

The Board believes that, following the Group's strengthened profitability, improved margin profile and sustained positive free cash flow, it is appropriate to establish a framework that enhances capital flexibility and supports long-term shareholder value creation.

The Company intends to utilise the existing shareholder authorisation granted at the Annual General Meeting to repurchase up to 10 per cent of the Company's issued share capital. Any repurchases would be funded from operating cash flow and distributable reserves and would not involve drawings under the Company's revolving credit facility.

The SBB provides the Company with flexibility in capital allocation. Repurchased shares may be cancelled to reduce the number of shares outstanding or held in treasury for potential future use, including possible share-based incentive arrangements. No share-based incentive plan has been approved at this time.

Henrik Molin, CEO and co-founder, commented:
" Physitrack exits 2025 with materially improved cash generation, stronger margins and a more focused operating model. Establishing a share buyback framework reflects the Board's confidence in the business and its commitment to disciplined capital allocation. We view buybacks, like dividends, as a legitimate shareholder value tool. This program provides flexibility to optimise our capital structure while continuing to invest in growth. "

Implementation of the program remains subject to approval from the Company's banking partner. The Board does not currently anticipate any impediment to obtaining such approval.

The timing, size and execution of any repurchases will remain at the discretion of the Board and will be conducted in accordance with the EU Market Abuse Regulation (MAR), applicable safe harbour rules and Nasdaq First North Premier Growth Market requirements.

No share repurchases have been made as of the date of this announcement.

Further updates will be provided in accordance with applicable disclosure requirements.

Enquiries regarding this announcement should be addressed to:

Henrik Molin, CEO and co-founder, Physitrack.
+44 208 133 9325
ir@physitrack.com
media@physitrack.com

About Physitrack

Physitrack PLC, founded in 2012, is a global digital healthcare provider, focused on the B2B wellness and virtual-first care markets. With staff with 12 nationalities on four continents, customers in 17 time zones, and end users in 187 countries, Physitrack is a truly global company.

The company has two business lines:

  1. Lifecare - SaaS platform tailored mainly to physiotherapy and musculoskeletal care, enabling practitioners to deliver clinical home exercises, education prescription, outcomes tracking, triaging and Telehealth.

  2. Wellness / Champion Health - SaaS platform for Employee Wellness and care powered by a combination of world-leading technology and wellness professionals based in the United Kingdom, Germany and the Nordics.

Physitrack PLC is headquartered in London, United Kingdom, and listed on Nasdaq First North Premier Growth Market (PTRK).

Visit us at
https://physitrackgroup.com/ (investor relations)
https://physitrack.com (product marketing)

About Champion Health

Champion Health, a subsidiary of Physitrack Plc, is a leader in corporate wellness technology, providing an innovative platform that empowers businesses to support their employees' well-being through personalised wellness action plans and advanced analytics.

Visit us at
https://championhealth.co.uk/

Attachments

Physitrack PLC announces intention to implement share buyback program

SOURCE: Physitrack PLC



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/physitrack-plc-announces-intention-to-implement-share-buyback-pro-1139474

© 2026 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.